Smith & Nephew (LON:SN – Get Free Report)‘s stock had its “overweight” rating reiterated by investment analysts at JPMorgan Chase & Co. in a report issued on Tuesday,Digital Look reports. They currently have a GBX 1,180 ($14.44) target price on the stock. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 19.43% from the company’s current price.
Smith & Nephew Stock Down 1.6 %
Shares of SN traded down GBX 16 ($0.20) during trading hours on Tuesday, reaching GBX 988 ($12.09). The company’s stock had a trading volume of 1,904,525 shares, compared to its average volume of 343,671. The firm has a fifty day moving average of GBX 978.94 and a 200 day moving average of GBX 1,073.80. The company has a market cap of £8.62 billion, a price-to-earnings ratio of 3,659.26, a price-to-earnings-growth ratio of 0.46 and a beta of 0.62. The company has a current ratio of 2.51, a quick ratio of 0.84 and a debt-to-equity ratio of 70.22.
Insider Activity
In other Smith & Nephew news, insider John Rogers purchased 71,920 shares of the company’s stock in a transaction dated Thursday, December 19th. The stock was purchased at an average price of GBX 972 ($11.89) per share, with a total value of £699,062.40 ($855,436.12). Also, insider Rupert Soames acquired 5,344 shares of the firm’s stock in a transaction dated Monday, November 11th. The shares were purchased at an average price of GBX 936 ($11.45) per share, with a total value of £50,019.84 ($61,208.81). 0.19% of the stock is currently owned by corporate insiders.
About Smith & Nephew
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Featured Articles
- Five stocks we like better than Smith & Nephew
- How to Read Stock Charts for Beginners
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- How to Invest in the FAANG Stocks
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.
